Amprius (AMPX) 10-Q 7 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Oct. 31, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-04321
Entity Registrant Name	AMPRIUS TECHNOLOGIES, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	98-1591811
Entity Address, Address Line One	1180 Page Avenue
Entity Address, City or Town	Fremont
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94538
City Area Code	800
Local Phone Number	425-8803
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		105,838,789
Entity Central Index Key	0001899287
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value
Trading Symbol	AMPX
Security Exchange Name	NYSE
Redeemable warrants
Document Information [Line Items]
Title of 12(b) Security	Redeemable warrants, each exercisable for one share of common stock at an exercise price of $11.50
Trading Symbol	AMPX.W
Security Exchange Name	NYSE

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,045	$ 45,761
Accounts receivable, net	4,590	1,265
Inventories	2,664	730
Deferred costs	0	779
Prepaid expenses and other current assets	2,641	1,987
Total current assets	44,940	50,522
Non-current assets:
Property, plant and equipment, net	23,968	21,760
Operating lease right-of-use assets, net	33,829	35,149
Other assets	1,470	305
Total assets	104,207	107,736
Current liabilities:
Accounts payable	4,934	3,341
Accrued and other current liabilities	4,196	5,594
Deferred revenue	1,817	3,434
Operating lease liabilities	2,053	1,088
Total current liabilities	13,000	13,457
Non-current liabilities:
Operating lease liabilities	35,208	34,479
Total liabilities	48,208	47,936
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock; $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock; $0.0001 par value; 950,000,000 shares authorized; 111,338,789 and 88,869,463 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	11	9
Additional paid-in capital	218,904	189,454
Accumulated deficit	(162,916)	(129,663)
Total stockholders’ equity	55,999	59,800
Total liabilities and stockholders’ equity	$ 104,207	$ 107,736

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	950,000,000	950,000,000
Common stock, issued (in shares)	111,338,789	88,869,463
Common stock, outstanding (in shares)	111,338,789	88,869,463

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue	$ 7,855	$ 2,798	$ 13,536	$ 5,109
Cost of revenue	12,956	7,046	29,613	15,906
Gross loss	(5,101)	(4,248)	(16,077)	(10,797)
Operating expenses:
Research and development	1,817	815	5,060	2,387
Selling, general and administrative	4,335	4,068	13,367	15,781
Total operating expenses	6,152	4,883	18,427	18,168
Loss from operations	(11,253)	(9,131)	(34,504)	(28,965)
Other income, net	403	639	1,251	1,923
Net loss	$ (10,850)	$ (8,492)	$ (33,253)	$ (27,042)
Weighted-average common shares outstanding:
Weighted-average common shares outstanding, basic (in shares)	110,408,303	86,354,067	99,202,799	85,411,590
Weighted-average common shares outstanding, diluted (in shares)	110,408,303	86,354,067	99,202,799	85,411,590
Net loss per share of common stock:
Net loss per share of common stock, basic (in dollars per share)	$ (0.10)	$ (0.10)	$ (0.34)	$ (0.32)
Net loss per share of common stock, diluted (in dollars per share)	$ (0.10)	$ (0.10)	$ (0.34)	$ (0.32)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2022		84,610,114
Beginning Balance at Dec. 31, 2022	$ 73,033	$ 8	$ 165,912	$ (92,887)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with an At Market Issuance Sales Agreement/stock purchase agreement, net of issuance cost (in shares)		331,351
Issuance of common stock in connection with an At Market Issuance Sales Agreement/Stock Purchase Agreement, net of issuance cost	2,376		2,376
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)		30,000
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	2		2
Stock-based compensation	726		726
Net loss	(9,102)			(9,102)
Ending Balance (in shares) at Mar. 31, 2023		84,971,465
Ending Balance at Mar. 31, 2023	67,035	$ 8	169,016	(101,989)
Beginning Balance (in shares) at Dec. 31, 2022		84,610,114
Beginning Balance at Dec. 31, 2022	73,033	$ 8	165,912	(92,887)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(27,042)
Ending Balance (in shares) at Sep. 30, 2023		87,642,244
Ending Balance at Sep. 30, 2023	65,756	$ 9	185,676	(119,929)
Beginning Balance (in shares) at Mar. 31, 2023		84,971,465
Beginning Balance at Mar. 31, 2023	67,035	$ 8	169,016	(101,989)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with an At Market Issuance Sales Agreement/stock purchase agreement, net of issuance cost (in shares)		875,772
Issuance of common stock in connection with an At Market Issuance Sales Agreement/Stock Purchase Agreement, net of issuance cost	8,177	$ 1	8,176
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)		146,223
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	1		1
Exercise of stock warrants (in shares)		100
Issuance of common stock upon exercise of stock warrants, net of issuance cost	1		1
Stock-based compensation	924		924
Net loss	(9,448)			(9,448)
Ending Balance (in shares) at Jun. 30, 2023		85,993,560
Ending Balance at Jun. 30, 2023	66,690	$ 9	178,118	(111,437)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with an At Market Issuance Sales Agreement/stock purchase agreement, net of issuance cost (in shares)		1,269,441
Issuance of common stock in connection with an At Market Issuance Sales Agreement/Stock Purchase Agreement, net of issuance cost	6,331		6,331
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)		379,243
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	112		112
Stock-based compensation	1,115		1,115
Net loss	(8,492)			(8,492)
Ending Balance (in shares) at Sep. 30, 2023		87,642,244
Ending Balance at Sep. 30, 2023	$ 65,756	$ 9	185,676	(119,929)
Beginning Balance (in shares) at Dec. 31, 2023	88,869,463	88,869,463
Beginning Balance at Dec. 31, 2023	$ 59,800	$ 9	189,454	(129,663)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with an At Market Issuance Sales Agreement/stock purchase agreement, net of issuance cost (in shares)		2,853,266
Issuance of common stock in connection with an At Market Issuance Sales Agreement/Stock Purchase Agreement, net of issuance cost	8,746		8,746
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)		551,436
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	28		28
Stock-based compensation	1,247		1,247
Net loss	(9,886)			(9,886)
Ending Balance (in shares) at Mar. 31, 2024		92,274,165
Ending Balance at Mar. 31, 2024	$ 59,935	$ 9	199,475	(139,549)
Beginning Balance (in shares) at Dec. 31, 2023	88,869,463	88,869,463
Beginning Balance at Dec. 31, 2023	$ 59,800	$ 9	189,454	(129,663)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (33,253)
Ending Balance (in shares) at Sep. 30, 2024	111,338,789	111,338,789
Ending Balance at Sep. 30, 2024	$ 55,999	$ 11	218,904	(162,916)
Beginning Balance (in shares) at Mar. 31, 2024		92,274,165
Beginning Balance at Mar. 31, 2024	59,935	$ 9	199,475	(139,549)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with an At Market Issuance Sales Agreement/stock purchase agreement, net of issuance cost (in shares)		1,043,053
Issuance of common stock in connection with an At Market Issuance Sales Agreement/Stock Purchase Agreement, net of issuance cost	2,074		2,074
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)		1,585,405
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	68		68
Exercise of stock warrants (in shares)		13,075,664
Issuance of common stock upon exercise of stock warrants, net of issuance cost	13,628	$ 2	13,626
Stock-based compensation	1,941		1,941
Net loss	(12,517)			(12,517)
Ending Balance (in shares) at Jun. 30, 2024		107,978,287
Ending Balance at Jun. 30, 2024	65,129	$ 11	217,184	(152,066)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exchange of stock warrants for shares of common stock (in shares)		3,073,200
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)		287,302
Stock-based compensation	1,720		1,720
Net loss	$ (10,850)			(10,850)
Ending Balance (in shares) at Sep. 30, 2024	111,338,789	111,338,789
Ending Balance at Sep. 30, 2024	$ 55,999	$ 11	$ 218,904	$ (162,916)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (33,253)	$ (27,042)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	4,908	2,765
Depreciation and amortization	2,917	1,318
Amortization of deferred costs	1,246	1,070
Non-cash operating lease expense	3,857	811
Changes in operating assets and liabilities:
Accounts receivable	(3,325)	(1,201)
Inventories	(1,934)	13
Deferred costs	(467)	(1,692)
Prepaid expenses and other current assets	(654)	101
Other assets	(6)	(9)
Accounts payable	3,287	1,226
Accrued and other current liabilities	(1,383)	2,308
Deferred revenue	(1,617)	306
Operating lease liabilities	(843)	(727)
Net cash used in operating activities	(27,267)	(20,753)
Cash flows from investing activities:
Purchase of property, plant and equipment	(6,834)	(11,799)
Net cash used in investing activities	(6,834)	(11,799)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock warrants	14,384	1
Payment of equity financing costs	(756)	(406)
Proceeds from exercise of stock options	96	115
Net cash provided by financing activities	24,585	16,252
Net decrease in cash, cash equivalents and restricted cash equivalents	(9,516)	(16,300)
Cash, cash equivalents and restricted cash equivalents, beginning of period	45,817	69,752
Cash, cash equivalents and restricted cash equivalents, end of period	36,301	53,452
Reconciliation of cash, cash equivalents and restricted cash equivalents shown on the condensed consolidated balance sheets:
Cash and cash equivalents	35,045	53,396
Restricted cash equivalents included in other assets	1,256	56
Total cash, cash equivalents and restricted cash equivalents	36,301	53,452
Supplemental non-cash investing and financing activities:
Unpaid purchases of property, plant and equipment	155	2,039
Increase in fair value of modified stock warrants	727	0
Unpaid financing costs from the issuance of shares of common stock	0	263
At Market Issuance Sales Agreement
Cash flows from financing activities:
Proceeds from issuance of common stock	10,861	0
Stock Purchase Agreement
Cash flows from financing activities:
Proceeds from issuance of common stock	$ 0	$ 16,542

Nature of Operations and Organi

Nature of Operations and Organization	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Organization	Nature of Operations and Organization Nature of Operations Amprius Technologies, Inc. (hereafter referred to as the “Company,” “we,” “us,” or “our”) develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (“EV”) and light electric vehicle (“LEV”) industries. We have been in commercial battery production since 2018 and our disruptive silicon anode technology is intended to enable batteries with higher energy density, higher power density and fast charging capabilities over a wide range of operating temperatures. Our headquarters is located in Fremont, California. Liquidity and Capital Resources As of September 30, 2024, we had cash and cash equivalents of $35.0 million. We believe that our cash and cash equivalents will be sufficient to fund our obligations over twelve months from the date these condensed consolidated financial statements are issued. In addition, we may receive additional funds from the issuance and sale of our shares of our common stock under the At Market Issuance Sales Agreement (the “Sales Agreement”), which we entered into with B. Riley Securities, Inc., Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC, as sales agents (the “Sales Agents”) on October 2, 2023. Under the Sales Agreement, we may offer and sell, from time to time, shares of our common stock for an aggregate offering price of not more than $100.0 million. During the nine months ended September 30, 2024 and from the date of the Sales Agreement through September 30, 2024, we sold shares of our common stock under the Sales Agreement resulting in aggregate net proceeds of approximately $10.9 million and $11.2 million, respectively. We may also receive additional funds if our stock warrants are exercised for cash. During the nine months ended September 30, 2024, we received a total of $13.6 million, after deducting stock issuance costs, from the cash exercise of our stock warrants at a temporarily reduced exercise price of $1.10 per warrant. Since our inception, we have incurred recurring losses and negative cash flows from operations. During the three and nine months ended September 30, 2024, we incurred a net loss of $10.9 million and $33.3 million, respectively, and at September 30, 2024, our accumulated deficit was $162.9 million. We expect to incur additional losses in the future as we scale our business and increase our operating expenditures, including our research and development spend. We expect to raise additional funds in order to meet our future operating and capital expenditure requirements, and we may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. If sufficient funding is not raised, we may need to reduce our spending activities, which may negatively affect our ability to achieve our operating goals. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional dilution. Other Risks and Uncertainties We face risks related to abrupt political change, terrorist activity, and armed conflict such as the military conflicts between Russia and Ukraine and in the Middle East. These military conflicts have led to volatility in the global economy, and may contribute to inflation, volatility in the credit and capital markets, and interruption in the global supply chain. Although these military conflicts did not have an adverse impact on us to-date, the future outcome of such conflicts is highly unpredictable and uncertain and may adversely affect our future financial condition, results of operations and cash flows. The COVID-19 pandemic was unprecedented and resulted in significant national and global economic disruption. The extent to which public health emergencies such as the COVID-19 pandemic may impact our business, financial condition, prospects and results of operations is highly uncertain and cannot be predicted.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated. The significant accounting policies described below, together with Note 1 and other notes that follow, are an integral part of the condensed consolidated financial statements. Unaudited Interim Condensed Consolidated Financial Statements The condensed consolidated balance sheet as of December 31, 2023, which has been derived from our audited consolidated financial statements as filed in our Annual Report on Form 10-K with the Securities and Exchange Commission (the “SEC”) on March 28, 2024, and the unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC regarding interim financial reporting. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). The condensed consolidated financial statements have been prepared on a basis consistent with the audited financial statements. In management’s opinion, all adjustments made were normal or recurring in nature and necessary for the fair statement of our financial position as of September 30, 2024, our results of operations during the three and nine months ended September 30, 2024 and 2023, and our cash flows during the nine months ended September 30, 2024 and 2023. The financial data and other financial information disclosed in the notes to these condensed consolidated financial statements are also unaudited. The results of operations during the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or any other period. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Emerging Growth Company We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Furthermore, the JOBS Act exempts an emerging growth company from being required to comply with new or revised accounting standards until private companies are required to comply with such standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected to not opt out of such extended transition period. This means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt such new or revised standard unless we are no longer deemed an emerging growth company. As a result, the accompanying condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances; the results of which form the basis for making judgements that are not readily apparent from other sources. Actual results could materially differ from management estimates using different assumptions or under different conditions. Our significant accounting estimates include useful lives of property, plant and equipment; valuation of deferred taxes; lower of cost or net realizable adjustment of inventory; incremental borrowing rate used in calculating lease obligations and right-of-use assets; and certain inputs used to measure the fair value of stock option grants using the Black-Scholes option-pricing model. Fair Value Measurements We had money market funds totaling $22.9 million and $36.7 million as of September 30, 2024 and December 31, 2023, respectively, which were measured at Level 1 fair value based on the active market price of the instruments and included in cash and cash equivalents and in other assets in the accompanying condensed consolidated balance sheets. We did not have assets or liabilities measured at fair value on a recurring basis using Level 2 or Level 3 inputs as of September 30, 2024 and December 31, 2023. There were no transfers of financial instruments between Level 1, Level 2 and Level 3 during the three and nine months ended September 30, 2024 and 2023. Restricted Cash Equivalents Restricted cash equivalents pertain to the amount of cash deposits required by our lessors to satisfy letter of credit requirements under our lease agreements. Restricted cash equivalents, which are included in other assets in the accompanying condensed consolidated balance sheets, were $1.3 million and $56 thousand as of September 30, 2024 and December 31, 2023, respectively. Concentration of Credit Risk Financial instruments that potentially subject us to concentration of credit risk include cash, cash equivalents, restricted cash equivalents and accounts receivable. Through September 30, 2024, we have not experienced losses on our financial assets held in financial institutions. Our allowance for expected credit losses on our accounts receivable was de minimis as of September 30, 2024 and none as of December 31, 2023. Many of our customers are in the aviation industry though our batteries have applications across all segments of electric mobility. An adverse impact on the aviation industry may affect our relationship with our customers, which could affect our future financial condition, results of operations and cash flows. As of September 30, 2024 and December 31, 2023, there were three customers that represented approximately 49% and 80%, respectively, of our total accounts receivable. During the three months ended September 30, 2024, there were four customers that individually represented 20%, 16%, 13% and 10% of our revenue compared to four customers that individually represented 40%, 22%, 15% and 12% of our revenue during the three months ended September 30, 2023. During the nine months ended September 30, 2024, there were three customers that individually represented 14%, 12% and 11% of our revenue compared to four customers that individually represented 32%, 14%, 13% and 12% of our revenue during the nine months ended September 30, 2023. Segment Reporting We have determined that the Chief Executive Officer is our Chief Operating Decision Maker (“CODM”). The CODM reviews financial information presented on an aggregate basis for the purposes of assessing our performance and making decisions on how to allocate resources. Accordingly, we have determined that we operate in a single operating and reportable segment. All of our revenues are geographically earned in the United States and our property, plant and equipment are located in the United States. Significant Accounting Policies As of September 30, 2024, there have been no changes to our significant accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2023. Recent Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220-40) . This ASU requires entities to disclose, in the notes to the financial statements, (i) amounts of (a) purchases of inventory, (b) employee compensation and (c) depreciation; (ii) include certain amounts that are already required to be disclosed under current U.S. GAAP in the same disclosure as the other disaggregation requirements; (iii) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (iv) the total amount of selling expenses and, in annual reporting periods, a definition of selling expenses. This ASU, which is effective starting on our annual reporting for the year ending December 31, 2027 and interim reporting periods beginning January 1, 2028, is required to be adopted either (i) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (ii) retrospectively to any or all prior periods presented in the financial statements. Early adoption is permitted. We are currently evaluating this ASU. We believe that the impact of the additional required disclosures will enhance our current financial statement disclosure. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . This ASU requires entities to disclose, among others, (i) specific categories in the rate reconciliation table, (ii) additional information for reconciling items that meet a quantitative threshold and (iii) the amount of income taxes paid on a disaggregated level. This ASU is required to be adopted on a prospective basis. As an emerging growth company, this ASU is effective starting on our annual reporting for the year ending December 31, 2026. Early adoption is permitted. We are currently evaluating this ASU. We believe that the impact of the additional required disclosures will enhance our current financial statement disclosure. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . This ASU requires entities to disclose, among others, (i) significant segment expenses that are regularly provided to the CODM for measuring segment profit or loss, (ii) amounts for other significant items by reportable segment and (iii) an explanation of how the CODM uses the reported measures of segment profit or loss in assessing segment performance and deciding resource allocation. This ASU is required to be adopted on a retrospective basis starting on our annual reporting for the year ending December 31, 2024. Early adoption is permitted. We are currently evaluating this ASU. We believe that the impact of the additional required disclosures will enhance our financial statement disclosure.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregation of Revenue We disaggregate our revenue from customers by the type of arrangement, primarily from the sale of battery products and from providing customization design services, as this depicts how the nature, amount, timing, and uncertainty of our revenue and cash flows are affected by economic factors. The table below shows the composition of revenue from customers, as disaggregated by type of arrangement in accordance with Topic 606, and other revenue, which consisted of government grants that were accounted for following the accounting standards from International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance (in thousands). Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Revenue from customers: Sale of battery products $ 6,055 $ 2,194 $ 11,736 $ 3,956 Customization design services 1,500 604 1,500 891 Total revenue from customers 7,555 2,798 13,236 4,847 Other revenue – government grants 300 — 300 262 Total revenue $ 7,855 $ 2,798 $ 13,536 $ 5,109 Revenue from the sale of battery products also includes bill-and-hold arrangements, which were $0.6 million and $1.4 million during the three and nine months ended September 30, 2024, respectively, and $0.3 million and $0.7 million during the three and nine months ended September 30, 2023, respectively. Contract Balances The timing of revenue recognition, billings and cash collections can result in accounts receivable, contract assets recorded as unbilled receivables, and contract liabilities recorded as deferred revenue. Accounts receivable represents our right to consideration that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable was $4.6 million, $1.3 million and $0.7 million as of September 30, 2024, December 31, 2023 and December 31, 2022, respectively. Contract assets primarily relate to the rights to consideration for progress on contractual requirements performed but not billed at the reporting date. The contract assets are transferred to accounts receivable when the rights become unconditional. We had no contract assets as of both September 30, 2024 and December 31, 2023. Contract liabilities consist primarily of deferred revenue, w hich is the amount of progress payments received or billed in advance of revenue recognition. Deferred revenue is subsequently recognized as revenue when the performance obligation is satisfied. Deferred revenue was $1.8 million, $3.4 million and $3.4 million as of September 30, 2024, December 31, 2023 and December 31, 2022, respectively. Deferred revenue as of September 30, 2024 decreased compared to prior periods primarily due to the recognition of a non-recurring customization design service that was completed in the current quarter. During t he three and nine months ended September 30, 2024, revenue recognized from the prior year deferred revenue balance was $0.9 million and $1.9 million, respectively. During the three and nine months ended September 30, 2023, revenue recognized from the prior year deferred revenue balance was $0.4 million and $0.9 million, respectively. Remaining Performance Obligations We have performance obligations associated with commitments in customer contracts for future services that have not yet been recognized as revenue. As of September 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligations related to customer contracts that were unsatisfied or partially unsatisfied, including deferred revenue, was approximately $14.4 million. Given the applicable contract terms, approximately $12.9 million is expected to be recognized as revenue within one year and approximately $1.5 million is expected to be recognized between two and five years. This amount does not include contracts to which the customer is not committed. The estimated timing of the recognition of remaining unsatisfied performance obligations is subject to change and is affected by changes to scope, changes in timing of delivery of products and services, or contract modifications.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in thousands): September 30, December 31, 2024 2023 Raw materials $ 168 $ 172 Work in process 138 113 Finished goods 2,358 445 Inventories $ 2,664 $ 730

Property, Plant and Equipment,

Property, Plant and Equipment, Net	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment, net consisted of the following (in thousands): September 30, December 31, 2024 2023 Production equipment $ 6,959 $ 6,253 Lab equipment 2,536 2,502 Leasehold improvements 11,217 11,152 Furniture, fixtures and other equipment 385 376 Construction in progress 14,838 10,527 Property, plant and equipment, at cost 35,935 30,810 Less: accumulated depreciation and amortization (11,967) (9,050) Property, plant and equipment, net $ 23,968 $ 21,760 Construction in progress consists primarily of production equipment that we purchased but have not yet placed in service, as well as pre-construction costs related to the planning of our GWh-scale manufacturing facility in Brighton, Colorado. Depreciation and amortization expense was $0.8 million and $2.9 million during the three and nine months ended September 30, 2024, respectively, and $0.4 million and $1.3 million during the three and nine months ended September 30, 2023, respectively.

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued and Other Current Liabilities	Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following (in thousands): September 30, December 31, 2024 2023 Accrued compensation and benefits $ 2,502 $ 3,070 Accrued professional fees 619 1,703 Accrued purchases of finished goods for resale 642 447 Other 433 374 Total accrued and other current liabilities $ 4,196 $ 5,594

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Common Stock and Preferred Stock As of September 30, 2024, we had a total of 1,000,000,000 shares of stock authorized to be issued, of which 950,000,000 shares are designated as common stock, $0.0001 par value per share, and 50,000,000 shares are designated as preferred stock, $0.0001 par value per share. Holders of common stock are entitled to one vote for each share held and entitled to receive dividends when and if declared by the board of directors. We have not declared any dividends through September 30, 2024. Equity Incentive Plans 2022 Equity Incentive Plan (“2022 Plan”) We adopted the 2022 Plan effective September 14, 2022. The 2022 Plan authorizes awards in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, or performance awards and may be granted to directors, employees or consultants. As of September 30, 2024, the total number of shares reserved for issuance under the 2022 Plan was 13,418,125, which includes the increase in shares reserved pursuant to the evergreen provisions contained in the 2022 Plan and the assumed awards that were withheld for payment of an exercise price or were forfeited due to failure to vest. The number of shares available for issuance under the 2022 Plan may be increased annually at the beginning of the fiscal year, subject to certain limitations. 2016 Equity Incentive Plan (“2016 Plan”) The 2016 Plan was terminated concurrently with the adoption of the 2022 Plan. However, the 2016 Plan continues to govern the terms and conditions of the outstanding awards previously granted under the 2016 Plan. The 2022 Plan and 2016 Plan are collectively referred to as the “Equity Incentive Plans.” To date, all grants made under the Equity Incentive Plans have been stock options or restricted stock units (“RSUs”). Stock Options Stock options granted under the Equity Incentive Plans provided an exercise price not less than 100% of the fair value at the grant date, unless the optionee is a 10% stockholder, in which case the option price will not be less than 110% of such fair market value. Options granted generally have a maximum term of 10 years from grant date or 90 days from the termination of the optionee, are exercisable upon vesting unless otherwise designated for early exercise by the board of directors at the time of grant, and generally vest over a period of four years. As of September 30, 2024, the total unrecognized stock-based compensation expense related to the unvested stock options was approximately $3.5 million, which we expect to recognize over a weighted-average period of 1.6 years. RSUs The fair value of RSUs is determined based upon the market closing price of our common stock on the date of grant. RSUs generally vest over a period of approximately four years from the date of grant, subject to the continued employment or services of the grantee . As of September 30, 2024, the total unrecognized stock-based compensation expense related to the unvested RSUs was approximately $12.0 million, which we expect to recognize over a weighted-average period of 3.1 years. Amprius, Inc. (“Amprius Holdings”) 2008 Stock Plan The stock-based compensation costs under the Amprius Holdings 2008 Stock Plan, which were associated with grants to certain individuals who provided services to our company, were already fully recognized as of September 30, 2024 and included in the accompanying condensed consolidated statements of operations, with a corresponding increase in additional paid-in capital. On October 23, 2024, in connection with the liquidation and dissolution of Amprius Holdings, we assumed all of Amprius Holdings’ outstanding stock options to purchase shares of Amprius Holdings Class A common stock under the Amprius Holdings 2008 Stock Plan and the Amprius Holdings Second Equity Incentive Plan. See Note 12 below for additional information. Employee Stock Purchase Plan We adopted the 2022 Employee Stock Purchase Plan (“ESPP”) effective September 14, 2022. As of September 30, 2024, the total number of shares reserved for issuance was 2,724,333, which may be increased annually at the beginning of the fiscal year, subject to certain limitations. The ESPP is intended to qualify under Section 423 of the U.S. Internal Revenue Code of 1986 (as amended) (the “Code”) and will provide eligible employees an opportunity to purchase our common stock at a discount through payroll deductions. We have not established an offering under the ESPP as of September 30, 2024. Executive Incentive Compensation Plan On September 14, 2022, our board of directors approved our Executive Incentive Compensation Plan, which will allow us to grant incentive awards to certain executive employees, generally payable in cash, based upon achieving specified goals. We have the right to settle the award by granting an equity award, which may be subject to vesting conditions. All awards under the Executive Incentive Compensation Plan will be subject to reduction, cancellation, forfeiture, or recoupment in accordance with any clawback policy that we are required to adopt pursuant to applicable laws. As of September 30, 2024, there were no awards granted under the Executive Incentive Compensation Plan. Common Stock Warrants On May 13, 2024, we offered the holders of the public and private warrants the opportunity to exercise their warrants for cash at a temporarily reduced exercise price of $1.10 per warrant. This cash tender offer expired on June 11, 2024. A total of 12,575,664 public warrants and 500,000 private warrants were exercised in connection with this cash tender offer. Gross proceeds from the exercise of the public and private warrants totaled $14.4 million. Incremental costs incurred, which were charged against the proceeds from the issuance of our shares of common stock, totaled $0.8 million. This cash tender offer was treated as a modification of the public and private warrants. However, we have not recognized the effect of such modification because the incremental fair value was de minimis. On June 24, 2024, we made a separate tender offer to the holders of the unexercised private warrants pursuant to which such holders were given the opportunity to exchange their warrants, on a cashless basis, for shares of our common stock based on an exchange ratio of 0.197 for each warrant validly tendered. This cashless tender offer expired on July 23, 2024. A total of 15,600,000 private warrants were exchanged for a total of 3,073,200 shares of our common stock in connection with this cashless tender offer. This cashless tender offer was treated as a modification of the private warrants. Such modification resulted in an increase in the private warrants’ fair value of approximately $0.7 million. The incremental fair value of the modified private warrants, which are classified as equity, is presented as an increase in additional paid-in capital on our condensed consolidated statements of stockholders’ equity. In addition, the incremental fair value is treated as a noncash deemed dividend and is presented as a reduction in additional paid-in capital, instead of a reduction in retained earnings due to our accumulated deficit position on our condensed consolidated statements of stockholders’ equity. Shown below is a summary of the activity of the stock warrants as of and during the nine months ended September 30, 2024: Public Private PIPE Total Outstanding, December 31, 2023 29,268,236 16,400,000 2,052,500 47,720,736 Exercise for cash (12,575,664) (500,000) — (13,075,664) Noncash exercise in exchange for — (15,600,000) — (15,600,000) Outstanding, September 30, 2024 16,692,572 300,000 2,052,500 19,045,072 The public warrants and private warrants, which expire on September 14, 2027, are exercisable for one share of our common stock at a price of $11.50 per warrant subject to adjustment pursuant to the Warrant Agreement, dated as of March 1, 2022, as amended. Holders of private warrants may be able to exercise their warrants on a cashless basis pursuant to the Warrant Agreement, but holders of public warrants cannot exercise on a cashless basis. The public warrants are listed on the NYSE and are redeemable by us when the price per share of our common stock equals or exceeds $18.00 per share for at least 20 trading days during a period of 30 consecutive trading days prior to the redemption date. The private warrants are not listed on any securities exchange and are not redeemable. The PIPE warrants, which expire on September 14, 2027, are substantially identical to the public warrants, except that the exercise price of each PIPE warrant is $12.50 per warrant and they are not listed on any securities exchange. In addition, the PIPE warrants are redeemable by us if the price per share of our common stock equals or exceeds $20.00 per share for at least 20 trading days during a period of 30 consecutive trading days prior to the redemption date. The warrants described above are classified as equity in accordance with the guidance under ASC 815-40, Derivatives and Hedging–Contracts in Entity’s Own Equity . Equity-classified contracts, such as stock warrants, are initially measured at fair value or allocated value. Any subsequent changes in fair value are not recognized as long as the contracts continue to be classified in equity. At Market Issuance Sales Agreement On October 2, 2023, we entered into the Sales Agreement with the Sales Agents, pursuant to which we may offer and sell, from time to time, through or to any Sales Agent, shares of our common stock with an aggregate offering price of not more than $100.0 million. From the date of the Sales Agreement through September 30, 2024, we sold shares of our common stock under the Sales Agreement resulting in aggregate net proceeds of approximately $11.2 million. Costs incurred related to the Sales Agreement, which were initially deferred and included in other assets in the accompanying condensed consolidated balance sheets, will be charged proportionally against the proceeds from the issuance of shares of common stock. The balance of unamortized deferred stock issuance costs was $0.2 million as of September 30, 2024. Common Stock Purchase Agreement On September 27, 2022, we entered into a Common Stock Purchase Agreement (the “Stock Purchase Agreement”) with B. Riley Principal Capital II, LLC (“BRPC II”), pursuant to which BRPC II committed to purchase shares of our common stock. We and BRPC II mutually agreed to terminate the Stock Purchase Agreement effective October 10, 2023. Stock-Based Compensation Stock-based compensation from stock options and RSUs under the Equity Incentive Plans and from stock options under the Amprius Holdings 2008 Stock Plan that we recorded were included in the following lines in the accompanying condensed consolidated statements of operations during the periods presented (in thousands) : Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Cost of revenue $ 223 $ 269 $ 632 $ 682 Research and development 248 27 688 74 Selling, general and administrative 1,249 819 3,588 2,009 Total stock-based compensation expense $ 1,720 $ 1,115 $ 4,908 $ 2,765

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesWe have no income tax expense as a result of the continued generation of net operating losses (“NOLs”), offset by a full valuation allowance recorded on such NOLs as we determined it is not more-likely-than-not that our NOLs will be utilized.

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	Leases As of September 30, 2024, we had non-cancelable operating leases for our corporate headquarters and manufacturing facilities located in Fremont, California and in Brighton, Colorado. Our Fremont lease, which expires in June 2027, provides us with an option to extend the term for one additional 5-year period and we determined with reasonable certainty that we will exercise such option. Our Brighton lease, which expires in May 2039, provides us with an option to extend the term for two additional 5-year periods, but we have not determined with reasonable certainty that we will exercise such option. Our operating leases do not contain any material residual value guarantees. We had no leases that were classified as finance leases as of September 30, 2024 and December 31, 2023. The components of lease expense during the three and nine months ended September 30, 2024 and 2023 are shown in the table below (in thousands): Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Operating lease expense $ 1,286 $ 304 $ 3,857 $ 810 Variable lease expense 667 79 1,074 210 Short-term lease expense 25 20 70 62 Total lease expense $ 1,978 $ 403 $ 5,001 $ 1,082 Other information about our operating leases during the nine months ended September 30, 2024 and 2023 are shown in the table below (amounts in thousands): Nine months ended September 30, 2024 2023 Cash paid for amounts included in the measurement of operating lease $ 843 $ 727 Right-of-use assets obtained in exchange for new operating lease liabilities $ — $ 5,241 Weighted-average remaining lease term 13.7 years 8.8 years Weighted-average discount rate 9.4 % 7.9 % Future operating lease payments, net of tenant improvement allowance, as of September 30, 2024 are as follows (in thousands): Year ending December 31: Amount Remainder of 2024 $ 471 2025 2,055 2026 3,929 2027 5,025 2028 5,185 2029 5,344 Thereafter 48,439 Total lease payments, net of tenant improvement allowance 70,448 Less - present value adjustments (33,187) Total operating lease liabilities $ 37,261

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies From time to time, we may be involved in lawsuits, claims or legal proceedings that arise in the ordinary course of business. We accrue a contingent liability when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Management believes that there are no claims against us for which the outcome is expected to have a material effect on our financial position, results of operations or cash flows.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts) : Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Numerator: Net loss $ (10,850) $ (8,492) $ (33,253) $ (27,042) Add - increase in net loss due to the increase (727) — (727) — Net loss attributable to common stockholders $ (11,577) $ (8,492) $ (33,980) $ (27,042) Denominator: Weighted-average number of common 110,408,303 86,354,067 99,202,799 85,411,590 Basic and diluted net loss per common share $ (0.10) $ (0.10) $ (0.34) $ (0.32) The amount of net loss was adjusted by the amount of the incremental fair value of the modified stock warrants described in Note 7 above. The following table summarizes the outstanding shares of potentially dilutive securities that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive: September 30, 2024 2023 Stock warrants 19,045,072 47,720,736 Stock options 11,019,724 13,432,871 RSUs 4,573,951 568,708 Total 34,638,747 61,722,315

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On October 23, 2024, Amprius Holdings, which owned an aggregate of 65.2 million shares, or 58.6%, of our common stock, voluntarily liquidated and dissolved. As a result of such liquidation and dissolution, Amprius Holdings distributed, on a pro rata basis, an aggregate of approximately 57.2 million shares of our common stock to its stockholders. In connection with the liquidation and dissolution of Amprius Holdings, and upon approval by our board of directors, we assumed all of Amprius Holdings’ outstanding stock options to purchase shares of Amprius Holdings Class A common stock in exchange for, among other things, Amprius Holdings contributing to us 5.5 million shares of our common stock that it owned and agreeing to reimburse our expenses incurred in connection with the assumption of those stock options. All of the shares of our common stock that were contributed by Amprius Holdings to us were cancelled and returned to our authorized but unissued share capital.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net loss	$ (10,850)	$ (12,517)	$ (9,886)	$ (8,492)	$ (9,448)	$ (9,102)	$ (33,253)	$ (27,042)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated.
Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated.
Unaudited Interim Condensed Consolidated Financial Statements	Unaudited Interim Condensed Consolidated Financial Statements The condensed consolidated balance sheet as of December 31, 2023, which has been derived from our audited consolidated financial statements as filed in our Annual Report on Form 10-K with the Securities and Exchange Commission (the “SEC”) on March 28, 2024, and the unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC regarding interim financial reporting. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). The condensed consolidated financial statements have been prepared on a basis consistent with the audited financial statements. In management’s opinion, all adjustments made were normal or recurring in nature and necessary for the fair statement of our financial position as of September 30, 2024, our results of operations during the three and nine months ended September 30, 2024 and 2023, and our cash flows during the nine months ended September 30, 2024 and 2023. The financial data and other financial information disclosed in the notes to these condensed consolidated financial statements are also unaudited. The results of operations during the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or any other period. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading.
Emerging Growth Company	Emerging Growth Company We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Furthermore, the JOBS Act exempts an emerging growth company from being required to comply with new or revised accounting standards until private companies are required to comply with such standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected to not opt out of such extended transition period. This means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt such new or revised standard unless we are no longer deemed an emerging growth company. As a result, the accompanying condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances; the results of which form the basis for making judgements that are not readily apparent from other sources. Actual results could materially differ from management estimates using different assumptions or under different conditions. Our significant accounting estimates include useful lives of property, plant and equipment; valuation of deferred taxes; lower of cost or net realizable adjustment of inventory; incremental borrowing rate used in calculating lease obligations and right-of-use assets; and certain inputs used to measure the fair value of stock option grants using the Black-Scholes option-pricing model.
Restricted Cash Equivalents	Restricted Cash Equivalents
Concentration of Credit Risk	Concentration of Credit Risk
Segment Reporting	Segment Reporting We have determined that the Chief Executive Officer is our Chief Operating Decision Maker (“CODM”). The CODM reviews financial information presented on an aggregate basis for the purposes of assessing our performance and making decisions on how to allocate resources. Accordingly, we have determined that we operate in a single operating and reportable segment. All of our revenues are geographically earned in the United States and our property, plant and equipment are located in the United States.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220-40) . This ASU requires entities to disclose, in the notes to the financial statements, (i) amounts of (a) purchases of inventory, (b) employee compensation and (c) depreciation; (ii) include certain amounts that are already required to be disclosed under current U.S. GAAP in the same disclosure as the other disaggregation requirements; (iii) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (iv) the total amount of selling expenses and, in annual reporting periods, a definition of selling expenses. This ASU, which is effective starting on our annual reporting for the year ending December 31, 2027 and interim reporting periods beginning January 1, 2028, is required to be adopted either (i) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (ii) retrospectively to any or all prior periods presented in the financial statements. Early adoption is permitted. We are currently evaluating this ASU. We believe that the impact of the additional required disclosures will enhance our current financial statement disclosure. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . This ASU requires entities to disclose, among others, (i) specific categories in the rate reconciliation table, (ii) additional information for reconciling items that meet a quantitative threshold and (iii) the amount of income taxes paid on a disaggregated level. This ASU is required to be adopted on a prospective basis. As an emerging growth company, this ASU is effective starting on our annual reporting for the year ending December 31, 2026. Early adoption is permitted. We are currently evaluating this ASU. We believe that the impact of the additional required disclosures will enhance our current financial statement disclosure. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . This ASU requires entities to disclose, among others, (i) significant segment expenses that are regularly provided to the CODM for measuring segment profit or loss, (ii) amounts for other significant items by reportable segment and (iii) an explanation of how the CODM uses the reported measures of segment profit or loss in assessing segment performance and deciding resource allocation. This ASU is required to be adopted on a retrospective basis starting on our annual reporting for the year ending December 31, 2024. Early adoption is permitted. We are currently evaluating this ASU. We believe that the impact of the additional required disclosures will enhance our financial statement disclosure.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Composition of Revenue	The table below shows the composition of revenue from customers, as disaggregated by type of arrangement in accordance with Topic 606, and other revenue, which consisted of government grants that were accounted for following the accounting standards from International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance (in thousands). Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Revenue from customers: Sale of battery products $ 6,055 $ 2,194 $ 11,736 $ 3,956 Customization design services 1,500 604 1,500 891 Total revenue from customers 7,555 2,798 13,236 4,847 Other revenue – government grants 300 — 300 262 Total revenue $ 7,855 $ 2,798 $ 13,536 $ 5,109

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following (in thousands): September 30, December 31, 2024 2023 Raw materials $ 168 $ 172 Work in process 138 113 Finished goods 2,358 445 Inventories $ 2,664 $ 730

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, plant and equipment, net consisted of the following (in thousands): September 30, December 31, 2024 2023 Production equipment $ 6,959 $ 6,253 Lab equipment 2,536 2,502 Leasehold improvements 11,217 11,152 Furniture, fixtures and other equipment 385 376 Construction in progress 14,838 10,527 Property, plant and equipment, at cost 35,935 30,810 Less: accumulated depreciation and amortization (11,967) (9,050) Property, plant and equipment, net $ 23,968 $ 21,760

Accrued and Other Current Lia_2

Accrued and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued and Other Current Liabilities	Accrued and other current liabilities consisted of the following (in thousands): September 30, December 31, 2024 2023 Accrued compensation and benefits $ 2,502 $ 3,070 Accrued professional fees 619 1,703 Accrued purchases of finished goods for resale 642 447 Other 433 374 Total accrued and other current liabilities $ 4,196 $ 5,594

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Outstanding Stock Warrants	Shown below is a summary of the activity of the stock warrants as of and during the nine months ended September 30, 2024: Public Private PIPE Total Outstanding, December 31, 2023 29,268,236 16,400,000 2,052,500 47,720,736 Exercise for cash (12,575,664) (500,000) — (13,075,664) Noncash exercise in exchange for — (15,600,000) — (15,600,000) Outstanding, September 30, 2024 16,692,572 300,000 2,052,500 19,045,072
Schedule of Stock-Based Compensation Expense	Stock-based compensation from stock options and RSUs under the Equity Incentive Plans and from stock options under the Amprius Holdings 2008 Stock Plan that we recorded were included in the following lines in the accompanying condensed consolidated statements of operations during the periods presented (in thousands) : Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Cost of revenue $ 223 $ 269 $ 632 $ 682 Research and development 248 27 688 74 Selling, general and administrative 1,249 819 3,588 2,009 Total stock-based compensation expense $ 1,720 $ 1,115 $ 4,908 $ 2,765

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of Components of Lease Expense	The components of lease expense during the three and nine months ended September 30, 2024 and 2023 are shown in the table below (in thousands): Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Operating lease expense $ 1,286 $ 304 $ 3,857 $ 810 Variable lease expense 667 79 1,074 210 Short-term lease expense 25 20 70 62 Total lease expense $ 1,978 $ 403 $ 5,001 $ 1,082 Other information about our operating leases during the nine months ended September 30, 2024 and 2023 are shown in the table below (amounts in thousands): Nine months ended September 30, 2024 2023 Cash paid for amounts included in the measurement of operating lease $ 843 $ 727 Right-of-use assets obtained in exchange for new operating lease liabilities $ — $ 5,241 Weighted-average remaining lease term 13.7 years 8.8 years Weighted-average discount rate 9.4 % 7.9 %
Schedule of Future Maturing Operating Lease Payments	Future operating lease payments, net of tenant improvement allowance, as of September 30, 2024 are as follows (in thousands): Year ending December 31: Amount Remainder of 2024 $ 471 2025 2,055 2026 3,929 2027 5,025 2028 5,185 2029 5,344 Thereafter 48,439 Total lease payments, net of tenant improvement allowance 70,448 Less - present value adjustments (33,187) Total operating lease liabilities $ 37,261

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Calculation of Basic and Diluted Net Loss Per Share	The following table presents the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts) : Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Numerator: Net loss $ (10,850) $ (8,492) $ (33,253) $ (27,042) Add - increase in net loss due to the increase (727) — (727) — Net loss attributable to common stockholders $ (11,577) $ (8,492) $ (33,980) $ (27,042) Denominator: Weighted-average number of common 110,408,303 86,354,067 99,202,799 85,411,590 Basic and diluted net loss per common share $ (0.10) $ (0.10) $ (0.34) $ (0.32)
Schedule of Potentially Dilutive Securities	The following table summarizes the outstanding shares of potentially dilutive securities that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive: September 30, 2024 2023 Stock warrants 19,045,072 47,720,736 Stock options 11,019,724 13,432,871 RSUs 4,573,951 568,708 Total 34,638,747 61,722,315

Nature of Operations and Orga_2

Nature of Operations and Organization - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended						9 Months Ended		12 Months Ended
	Oct. 02, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	May 13, 2024	Dec. 31, 2023	Mar. 01, 2022
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash and cash equivalents		$ 35,045			$ 53,396			$ 35,045	$ 53,396	$ 35,045		$ 45,761
Proceeds from issuance of common stock upon exercise of stock warrants		$ 13,600						$ 14,384	1
Exercise price (in dollars per share)		$ 1.10						$ 1.10		$ 1.10	$ 1.10		$ 11.50
Net loss		$ (10,850)	$ (12,517)	$ (9,886)	$ (8,492)	$ (9,448)	$ (9,102)	$ (33,253)	$ (27,042)
Accumulated deficit		$ (162,916)						(162,916)		$ (162,916)		$ (129,663)
At Market Issuance Sales Agreement
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Aggregate offering price	$ 100,000
Proceeds from the sale of shares of common stock								$ 10,900		$ 11,200

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restricted cash equivalents	$ 1,256,000	$ 56,000	$ 1,256,000	$ 56,000	$ 56,000
Accounts receivable
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Allowance for expected credit losses on our accounts receivable	$ 0		$ 0		$ 0
Accounts receivable | Customer concentration risk | Three customers
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage			49%		80%
Revenue benchmark | Customer concentration risk | Customer One
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage	20%	40%	14%	32%
Revenue benchmark | Customer concentration risk | Customer Two
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage	16%	22%	12%	14%
Revenue benchmark | Customer concentration risk | Customer Three
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage	13%	15%	11%	13%
Revenue benchmark | Customer concentration risk | Customer Four
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage	10%	12%		12%
Level 1 | Money Market Funds
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash equivalents	$ 22,900,000		$ 22,900,000		$ 36,700,000

Revenue - Schedule of Compositi

Revenue - Schedule of Composition of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 7,855	$ 2,798	$ 13,536	$ 5,109
Total revenue from customers
Disaggregation of Revenue [Line Items]
Revenue	7,555	2,798	13,236	4,847
Sale of battery products
Disaggregation of Revenue [Line Items]
Revenue	6,055	2,194	11,736	3,956
Customization design services
Disaggregation of Revenue [Line Items]
Revenue	1,500	604	1,500	891
Other revenue – government grants
Disaggregation of Revenue [Line Items]
Revenue	$ 300	$ 0	$ 300	$ 262

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 7,855,000	$ 2,798,000	$ 13,536,000	$ 5,109,000
Accounts receivable, net	4,590,000		4,590,000		$ 1,265,000	$ 700,000
Contract asset	0		0		0
Contract liability	1,800,000		1,800,000		$ 3,400,000	$ 3,400,000
Revenue recognized	900,000	400,000	1,900,000	900,000
Bill-and-hold
Disaggregation of Revenue [Line Items]
Revenue	$ 600,000	$ 300,000	$ 1,400,000	$ 700,000

Revenue - Performance Obligatio

Revenue - Performance Obligation (Details) $ in Millions	Sep. 30, 2024 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 14.4
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 12.9
Revenue, remaining performance obligation, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 1.5
Revenue, remaining performance obligation, period	4 years

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 168	$ 172
Work in process	138	113
Finished goods	2,358	445
Inventories	$ 2,664	$ 730

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 35,935	$ 30,810
Less: accumulated depreciation and amortization	(11,967)	(9,050)
Property, plant and equipment, net	23,968	21,760
Production equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	6,959	6,253
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	2,536	2,502
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	11,217	11,152
Furniture, fixtures and other equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	385	376
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 14,838	$ 10,527

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 0.8	$ 0.4	$ 2.9	$ 1.3

Accrued and Other Current Lia_3

Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued compensation and benefits	$ 2,502	$ 3,070
Accrued professional fees	619	1,703
Accrued purchases of finished goods for resale	642	447
Other	433	374
Total accrued and other current liabilities	$ 4,196	$ 5,594

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) $ / shares in Units, $ in Thousands					3 Months Ended						9 Months Ended		12 Months Ended
	Jun. 24, 2024 USD ($)	May 13, 2024 $ / shares shares	Oct. 02, 2023 USD ($)	Sep. 14, 2022 day $ / shares	Sep. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 shares	Mar. 31, 2024 shares	Sep. 30, 2023 USD ($) shares	Jun. 30, 2023 shares	Mar. 31, 2023 shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 $ / shares shares	Mar. 01, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares authorized (in shares)					1,000,000,000						1,000,000,000		1,000,000,000
Common stock, authorized (in shares)					950,000,000						950,000,000		950,000,000	950,000,000
Common stock, par value (in dollars per share) | $ / shares					$ 0.0001						$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)					50,000,000						50,000,000		50,000,000	50,000,000
Preferred stock, par value (in dollars per share) | $ / shares					$ 0.0001						$ 0.0001		$ 0.0001	$ 0.0001
Number of securities called by each warrant (in shares)					1						1		1		1
Unrecognized compensation expense | $					$ 3,500						$ 3,500		$ 3,500
Exercise price (in dollars per share) | $ / shares		$ 1.10			$ 1.10						$ 1.10		$ 1.10		$ 11.50
Exercised (in shares)											13,075,664
Proceeds from issuance of common stock upon exercise of stock warrants | $					$ 13,600						$ 14,384	$ 1
Stock issuance costs | $											800
Increase in fair value of modified stock warrants | $					$ 727			$ 0			727	$ 0
Unamortized deferred stock issuance costs | $											200
Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
New shares issued (in shares)						1,043,053	2,853,266	1,269,441	875,772	331,351
At Market Issuance Sales Agreement
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Aggregate offering price | $			$ 100,000
Proceeds from the sale of shares of common stock | $											$ 10,900		$ 11,200
Public warrants
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercised (in shares)		12,575,664									12,575,664
Average price per share of redeemable warrants (in dollars per share) | $ / shares				$ 18
Warrants, redeem, threshold trading days | day				20
Warrants, redeem, threshold consecutive trading days | day				30
Private warrants
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercised (in shares)		500,000			15,600,000						500,000
New shares issued (in shares)					3,073,200
Increase in fair value of modified stock warrants | $	$ 700
Private warrants | Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Conversion ratio, stock warrant into common stock	0.197
PIPE warrants
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price (in dollars per share) | $ / shares					$ 12.50						$ 12.50		$ 12.50
Exercised (in shares)											0
Average price per share of redeemable warrants (in dollars per share) | $ / shares				$ 20
Warrants, redeem, threshold trading days | day				20
Warrants, redeem, threshold consecutive trading days | day				30
Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average period to be recognized											1 year 7 months 6 days
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting period											4 years
Weighted average period to be recognized											3 years 1 month 6 days
Unrecognized compensation cost | $					$ 12,000						$ 12,000		$ 12,000
2022 Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for future issuance (in shares)					13,418,125						13,418,125		13,418,125
Equity Incentive Plans
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price as a percentage of fair value											100%
Percentage of optionee for option price											10%
Exercise price as a percentage of fair value, ten percent stockholders											110%
Award expiration period											10 years
Equity Incentive Plans | Employee stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award vesting period											4 years
Employee Stock Purchase Plan | Employee stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reserved for issuance (Shares)					2,724,333						2,724,333		2,724,333
Executive Incentive Compensation Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted (in shares)											0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock Warrant (Details) - shares		3 Months Ended	9 Months Ended
	May 13, 2024	Sep. 30, 2024	Sep. 30, 2024
Summary Of The Activity Of The Stock Warrants [Roll Forward]
Warrants outstanding, beginning balance (in shares)			47,720,736
Exercised on a cash basis (in shares)			(13,075,664)
Exercised on a cashless basis (in shares)			(15,600,000)
Warrants outstanding, ending balance (in shares)		19,045,072	19,045,072
Public warrants
Summary Of The Activity Of The Stock Warrants [Roll Forward]
Warrants outstanding, beginning balance (in shares)			29,268,236
Exercised on a cash basis (in shares)	(12,575,664)		(12,575,664)
Exercised on a cashless basis (in shares)			0
Warrants outstanding, ending balance (in shares)		16,692,572	16,692,572
Private warrants
Summary Of The Activity Of The Stock Warrants [Roll Forward]
Warrants outstanding, beginning balance (in shares)			16,400,000
Exercised on a cash basis (in shares)	(500,000)	(15,600,000)	(500,000)
Exercised on a cashless basis (in shares)			(15,600,000)
Warrants outstanding, ending balance (in shares)		300,000	300,000
PIPE warrants
Summary Of The Activity Of The Stock Warrants [Roll Forward]
Warrants outstanding, beginning balance (in shares)			2,052,500
Exercised on a cash basis (in shares)			0
Exercised on a cashless basis (in shares)			0
Warrants outstanding, ending balance (in shares)		2,052,500	2,052,500

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,720	$ 1,115	$ 4,908	$ 2,765
Cost of revenue
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	223	269	632	682
Research and development
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	248	27	688	74
Selling, general and administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,249	$ 819	$ 3,588	$ 2,009

Income Taxes (Details)

Income Taxes (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Income Tax Disclosure [Abstract]
Income tax expense	$ 0

Leases - Narrative (Details)

Leases - Narrative (Details)	Sep. 30, 2024 lease extensionOption	Dec. 31, 2023 lease
Lessee, Lease, Description [Line Items]
Number of finance leases (in leases) | lease	0	0
Fremont, California Lease | Minimum
Lessee, Lease, Description [Line Items]
Number of extension options	1
Fremont, California Lease | Maximum
Lessee, Lease, Description [Line Items]
Lease term (in years)	5 years
Brighton, Colorado | Minimum
Lessee, Lease, Description [Line Items]
Number of extension options	2
Brighton, Colorado | Maximum
Lessee, Lease, Description [Line Items]
Lease term (in years)	5 years

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Operating lease expense	$ 1,286	$ 304	$ 3,857	$ 810
Variable lease expense	667	79	1,074	210
Short-term lease expense	25	20	70	62
Total lease expense	$ 1,978	$ 403	$ 5,001	$ 1,082

Leases - Schedule of Lease Term

Leases - Schedule of Lease Term and Discount Rate (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 843	$ 727
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 0	$ 5,241
Weighted-average remaining lease term	13 years 8 months 12 days		8 years 9 months 18 days
Weighted-average discount rate	9.40%		7.90%

Leases - Schedule of Future Mat

Leases - Schedule of Future Maturing Operating Lease Payments (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Leases [Abstract]
Remainder of 2024	$ 471
2025	2,055
2026	3,929
2027	5,025
2028	5,185
2029	5,344
Thereafter	48,439
Total lease payments, net of tenant improvement allowance	70,448
Less - present value adjustments	(33,187)
Total operating lease liabilities	$ 37,261

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator:
Net loss	$ (10,850)	$ (12,517)	$ (9,886)	$ (8,492)	$ (9,448)	$ (9,102)	$ (33,253)	$ (27,042)
Add - increase in net loss due to the increase in fair value of modified stock warrants	(727)			0			(727)	0
Net loss attributable to common stockholders	(11,577)			(8,492)			(33,980)	(27,042)
Net loss attributable to common stockholders	$ (11,577)			$ (8,492)			$ (33,980)	$ (27,042)
Denominator:
Weighted-average number of common shares outstanding, basic (in shares)	110,408,303			86,354,067			99,202,799	85,411,590
Weighted-average number of common shares outstanding, diluted (in shares)	110,408,303			86,354,067			99,202,799	85,411,590
Basic net loss per common share (in dollars per share)	$ (0.10)			$ (0.10)			$ (0.34)	$ (0.32)
Diluted net loss per common share (in dollars per share)	$ (0.10)			$ (0.10)			$ (0.34)	$ (0.32)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of Potentially Dilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the computation of net loss per share (in shares)	34,638,747	61,722,315	34,638,747	61,722,315
Stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the computation of net loss per share (in shares)	19,045,072	47,720,736	19,045,072	47,720,736
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the computation of net loss per share (in shares)	11,019,724	13,432,871	11,019,724	13,432,871
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the computation of net loss per share (in shares)	4,573,951	568,708	4,573,951	568,708

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent event - Amprius Holdings - $ / shares shares in Millions	Oct. 23, 2024	Oct. 22, 2024
Subsequent Event [Line Items]
Common stock voluntarily liquidated and dissolved (in shares)		65.2
Common stock voluntarily liquidated and dissolved (as percent)		58.60%
Pro rata basis of common stock (in shares)	57.2
Common stock reimbursed (in shares)	5.5
Weighted average exercise price (in dollars per share)	$ 2.10
Stock options
Subsequent Event [Line Items]
Issuance of common stock upon exercise of stock options (in shares)	7